跳至主要内容
临床试验/NCT06488781
NCT06488781招募中2 期

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (APPOINT 2.0): A Multi-center Randomized Controlled Trial

University of Oklahoma1 个研究点 分布在 1 个国家目标入组 787 人开始时间: 2025年4月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
787
试验地点
1
主要终点
Rate of cesarean delivery

研究概览

简要总结

Obesity increases the risk of pregnancy complications, including puerperal infections and cesarean delivery, and risk rises with increasing body mass index (BMI). Since obese women are more likely to have comorbidities that would necessitate delivery prior to their due date (i.e. prior to 40 weeks gestation), and class III obesity specifically is an indication for delivery by 39 weeks, these patients have a high rate of labor induction. In nulliparous women from the general population (obese and non-obese), labor induction at 39 weeks (compared to expectant management) is associated with less maternal morbidity and a lower cesarean rate. Researchers previously conducted a pilot randomized placebo-controlled trial in obese, nulliparous women undergoing labor induction at term and found that the cesarean delivery rate was lower in women who received a prophylactic antibiotic regimen during labor compared with those who received the placebo. Researchers proposed multi-center trial aims to test this hypothesis in a large sample with adequate power to determine whether prophylactic antibiotics during labor are associated with a decrease in the rate of cesarean delivery in term, nulliparous, obese women. If the findings from the pilot trial are confirmed, this would represent a novel intervention to decrease the cesarean delivery rate in a subset of women at highest risk for cesarean-related complications.

详细描述

This is a multi-center randomized placebo-controlled trial in which nulliparous women with obesity who are undergoing induction of labor at term and not receiving IAP for GBS will be recruited (n=787). The participants will be randomized 1:1 to receive either prophylactic antibiotics during their labor induction (azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses) or like-appearing placebos. The participants and their obstetrical providers will be blinded to the study intervention. The study will be conducted with an identical protocol at six study sites. Trained research nurses/assistants at each study site will consent and enroll participants, collect biospecimens, and collect demographic information and data on pregnancy and neonatal outcomes, and will convey this data to the primary site for analysis.

Researchers hypothesize that the group that receives the study drug regimen of prophylactic antibiotics during induction of labor will have a lower rate of cesarean delivery than the group that receives the placebo. They also hypothesize that the group that receives the study drug regimen will have a lower rate of puerperal infection than the placebo group.

Nulliparous women with obesity who are undergoing induction of labor at term will be eligible for participation in the study. Across all sites, 787 total subjects will be recruited.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Study participants, clinical personnel, and members of the research team responsible for collecting clinical outcomes will be blinded to the treatment group allocation. The research pharmacist at each site and the research analyst generating the randomization scheme will be the only study team members to know the treatment group allocation.

入排标准

年龄范围
15 Years 至 45 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • No prior deliveries at or beyond 20 weeks gestation
  • Undergoing induction of labor
  • Gestational age 37 weeks or more
  • Age 15-45
  • Not receiving IAP for GBS prophylaxis

排除标准

  • Fetal death prior to labor induction
  • Known fetal anomaly
  • Multiple gestation
  • Ruptured membranes for more than 12 hours
  • Chorioamnionitis or other infection requiring antibiotics at the start of the labor induction
  • Previous myometrial surgery
  • Allergy to azithromycin or beta-lactam antibiotics

研究组 & 干预措施

Prophylactic antibiotics

Active Comparator

Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses

干预措施: Azithromycin (Drug)

Placebo

Placebo Comparator

Placebos, similar in appearance, in place of azithromycin and cefazolin

干预措施: Placebo (Drug)

结局指标

主要结局

Rate of cesarean delivery

时间窗: 30 days postpartum

Determine whether a prophylactic antibiotic regimen during labor induction will decrease the rate of cesarean delivery in obese, nulliparous women undergoing induction of labor

次要结局

  • Rate of postpartum hemorrhage(30 days postpartum)
  • Rate of blood transfusion(30 days postpartum)
  • Rate of intensive care unit admission(30 days postpartum)
  • Rate of hospital readmission(30 days postpartum)
  • Rate of indications for cesarean delivery(30 days postpartum)
  • Rate of chorioamnionitis development(30 days postpartum)
  • Rate of cesarean wound infection(30 days postpartum)
  • Rate of endometritis(30 days postpartum)
  • Rate of necrotizing enterocolitis(30 days postpartum)
  • Periventricular leukomalacia(30 days postpartum)
  • Rate of intraventricular hemorrhage(30 days postpartum)
  • Neonatal death(30 days postpartum)
  • Maternal hospital stay(30 days postpartum)
  • Neonate hospital stay(30 days postpartum)
  • Rate of NICU admission(30 days postpartum)
  • APGAR score(30 days postpartum)
  • Rate of respiratory distress syndrome(30 days postpartum)
  • Rate of sepsis(30 days postpartum)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验